Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s stock price traded down 40% during trading on Wednesday. The company traded as low as $1.14 and last traded at $1.14. 200 shares were traded during mid-day trading, a decline of 100% from the average session volume of 68,153 shares. The stock had previously closed at $1.90.
Mesoblast Price Performance
The stock’s 50 day simple moving average is $1.82 and its 200-day simple moving average is $1.69.
Mesoblast Company Profile
Mesoblast Limited is a biotechnology company focused on developing cellular medicines for serious inflammatory and immune-mediated diseases. The company’s therapies are based primarily on its proprietary mesenchymal lineage stromal cell technology, which is designed to regulate excessive immune responses and inflammation and support tissue repair.
Mesoblast’s lead product, Ryoncil (remestemcel-L), is an allogeneic mesenchymal stromal cell therapy approved in the United States for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older.
Further Reading
- Five stocks we like better than Mesoblast
- Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
- Why Concentra’s Quiet Healthcare Business Keeps Winning
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
